Rare Functioning Pancreatic Endocrine Tumors

a Department of Gastroenterology, Beaujon Hospital, Clichy , France; b Department of Oncology, Institut Catala d’Oncologia, Barcelona , Spain; c Department of Surgery, Verona University, Verona , Italy; d Department of Endocrinology and Metabolism, Genimatas Hospital, Athens , Greece; e Department of Gastroenterology, Beaujon Hospital, Clichy , France; f Department of Endocrinology, Erasmus MC University, Rotterdam , The Netherlands; g Department of Internal Medicine, Martin University, Martin , Slovakia; h Department of Propaedeutic Internal Medicine, Laiko Hospital, Athens , Greece; i Department of Nuclear Medicine, Erasmus MC University, Rotterdam , The Netherlands; j Department of Gastroenterology, Beaujon Hospital, Clichy , France; k Department of Gastroenterology, Royal Free Hospital, London , UK; l Department of Cell Biology, National Institute of Health, Bethesda, Md. , USA; m Department of Endocrinology, University Hospital, Uppsala , Sweden

[1]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[2]  C. Heidecke,et al.  Laserinduzierte Thermotherapie (LITT) von Lebertumoren in zentraler Lokalisation : Ergebnisse und Komplikationen , 2005 .

[3]  R. Bale,et al.  Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  W. Hiddemann,et al.  Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  G. Nikou,et al.  VIPomas: an update in diagnosis and management in a series of 11 patients. , 2005, Hepato-gastroenterology.

[6]  M. Bergström,et al.  Developments in PET for the detection of endocrine tumours. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[7]  M. Bergström,et al.  Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography , 2005 .

[8]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Krenning,et al.  Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours , 2005 .

[11]  G. Thiéfin,et al.  Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. , 2004, Gastroenterologie clinique et biologique.

[12]  B. Skogseid,et al.  High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. , 2004, European journal of endocrinology.

[13]  O. Nilsson,et al.  Liver Transplantation for Treatment of Metastatic Neuroendocrine Tumors , 2004, Annals of the New York Academy of Sciences.

[14]  T. de Baère,et al.  The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? , 2004, European journal of cancer.

[15]  N. Fazio,et al.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Jensen,et al.  Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: A Prospective Study of 107 Cases and Comparison With 1009 Cases From the Literature , 2004, Medicine.

[17]  P. Ruszniewski,et al.  Ablative therapies for liver metastases of digestive endocrine tumours. , 2003, Endocrine-related cancer.

[18]  U. Mansmann,et al.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[20]  W. Gedroyc,et al.  MR-guided laser thermal ablation of primary and secondary liver tumours. , 2003, Clinical radiology.

[21]  J. Clain,et al.  Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. , 2002, Gastrointestinal endoscopy.

[22]  I. Sobhani,et al.  Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  G. Åkerström,et al.  Radiofrequency Tissue Ablation Using Cooled Tip for Liver Metastases of Endocrine Tumors , 2002, World Journal of Surgery.

[24]  E. Berber,et al.  Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases , 2002, World Journal of Surgery.

[25]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[27]  E. Nitzsche,et al.  Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. , 2001, Radiology.

[28]  M. A. Chastain.  The Glucagonoma Syndrome: A Review of its Features and Discussion of New Perspectives , 2001, The American journal of the medical sciences.

[29]  T. de Baère,et al.  Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. , 2001, European journal of cancer.

[30]  E P Krenning,et al.  Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.

[32]  U. Tylén,et al.  Interventional Treatment of Gastrointestinal Neuroendocrine Tumours , 2000, Digestion.

[33]  P. Ruszniewski,et al.  Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors , 2000, Digestion.

[34]  J. Soga,et al.  Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. , 1999, Journal of experimental & clinical cancer research : CR.

[35]  J. Doppman,et al.  Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. K. Martin,et al.  Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. , 1998, Surgery.

[37]  J. Soga,et al.  Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. , 1998, Journal of experimental & clinical cancer research : CR.

[38]  D. Le Guludec,et al.  Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  L. Kvols,et al.  Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. , 1996, Mayo Clinic proceedings.

[40]  G. Åkerström.  Management of Carcinoid Tumors of the Stomach, Duodenum, and Pancreas , 1996, World Journal of Surgery.

[41]  D. Morris,et al.  Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors , 1995, Cancer.

[42]  M. Clouse,et al.  Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. , 1994, Digestion.

[43]  M. Ychou,et al.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors a prospective phase II study in 24 patients , 1993, Cancer.

[44]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[45]  J. Rastad,et al.  Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. , 1991, The Journal of clinical endocrinology and metabolism.

[46]  Y. Morioka,et al.  Clinical pathology of endocrine tumors of the pancreas , 1991, Digestive Diseases and Sciences.

[47]  E. Wilander,et al.  Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients , 1990, Journal of internal medicine.

[48]  A. Vinik,et al.  Treatment of endocrine tumors of the pancreas. , 1989, Endocrinology and metabolism clinics of North America.

[49]  R. Jensen,et al.  Cushing's syndrome in patients with the Zollinger-Ellison syndrome. , 1986, The New England journal of medicine.

[50]  K. Öberg,et al.  SUCCESSFUL TREATMENT OF THERAPY-RESISTANT PANCREATIC CHOLERA WITH HUMAN LEUCOCYTE INTERFERON , 1985, The Lancet.

[51]  S. Bloom,et al.  Morphologic patterns and diagnostic criteria of VIP‐producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases , 1983, Cancer.

[52]  P. Guillausseau,et al.  [Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases]. , 1982, Gastroenterologie clinique et biologique.

[53]  T. Adrian,et al.  Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). , 1981, British medical journal.

[54]  A. M. Ebeid,et al.  "Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas. , 1977, The New England journal of medicine.

[55]  A. Morrison,et al.  Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. , 1958, The American journal of medicine.

[56]  N. Hosten,et al.  [Laser-induced thermotherapy (LITT) of tumors of the liver in central location: results and complications]. , 2005, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[57]  B. Långstrom,et al.  Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. , 2005, The Journal of clinical endocrinology and metabolism.

[58]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[59]  L. Kvols,et al.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  T. de Baère,et al.  Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors , 2002, European Radiology.

[61]  F. Wessels,et al.  Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. , 2001, The Journal of surgical research.

[62]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.

[63]  L. Sobin,et al.  Histological Classification of Endocrine Tumours , 2000 .

[64]  K. Öberg,et al.  An update of the medical treatment of malignant endocrine pancreatic tumors. , 1993, Acta oncologica.

[65]  V. Go,et al.  Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut , 1989 .

[66]  D. Wynick,et al.  Glucagonoma syndrome. , 1987, The American journal of medicine.